Skip to main content
NCBI home page
Journal of Virology logoLink to Journal of Virology
. 1988 Sep;62(9):3536–3539. doi: 10.1128/jvi.62.9.3536-3539.1988

Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.

M Roivainen 1, T Hovi 1
PMCID: PMC253485  PMID: 2841503

Abstract

We have exposed 22 independent type 2 poliovirus isolates to human intestinal fluid and purified trypsin. In all cases the virus retained its infectivity, while polyacrylamide gel electrophoresis of viral proteins showed disappearance of the VP1 bands. Concomitantly, the viruses became resistant to antigenic site 1-specific monoclonal antibodies, indicating that the cleavage took place at the antigenic site 1. Sera from persons immunized solely with the inactivated poliovirus vaccine (IPV) neutralized intact type 2 polioviruses more readily than the corresponding trypsin-cleaved virus preparations. The ratio between the neutralization indices for the intact and trypsin-cleaved type 2 polioviruses was not significantly changed by a dose of trivalent oral poliovirus vaccine given to children previously immunized with IPV. These results indicate that while the antigenic site 1 of type 2 poliovirus is immunogenic in humans when IPV is used, the relative role of this antigenic site in human immunity appears to be less critical than that in the case of type 3 polioviruses. Before we obtained these results, only antigenic site 1 had been shown to be immunogenic in type 2 polioviruses.

Full text

PDF
3536

Images in this article

3537Image
on p.3537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fricks C. E., Icenogle J. P., Hogle J. M. Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles. J Virol. 1985 Jun;54(3):856–859. doi: 10.1128/jvi.54.3.856-859.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Hogle J. M., Chow M., Filman D. J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985 Sep 27;229(4720):1358–1365. doi: 10.1126/science.2994218. [DOI] [PubMed] [Google Scholar]
  3. Hovi T., Cantell K., Huovilainen A., Kinnunen E., Kuronen T., Lapinleimu K., Pöyry T., Roivainen M., Salama N., Stenvik M. Outbreak of paralytic poliomyelitis in Finland: widespread circulation of antigenically altered poliovirus type 3 in a vaccinated population. Lancet. 1986 Jun 21;1(8495):1427–1432. doi: 10.1016/s0140-6736(86)91566-7. [DOI] [PubMed] [Google Scholar]
  4. Icenogle J. P., Minor P. D., Ferguson M., Hogle J. M. Modulation of humoral response to a 12-amino-acid site on the poliovirus virion. J Virol. 1986 Oct;60(1):297–301. doi: 10.1128/jvi.60.1.297-301.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. La Monica N., Kupsky W. J., Racaniello V. R. Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies. Virology. 1987 Dec;161(2):429–437. doi: 10.1016/0042-6822(87)90136-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  7. Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis. 1984 May-Jun;6 (Suppl 2):S457–S460. doi: 10.1093/clinids/6.supplement_2.s457. [DOI] [PubMed] [Google Scholar]
  8. Minor P. D., Ferguson M., Evans D. M., Almond J. W., Icenogle J. P. Antigenic structure of polioviruses of serotypes 1, 2 and 3. J Gen Virol. 1986 Jul;67(Pt 7):1283–1291. doi: 10.1099/0022-1317-67-7-1283. [DOI] [PubMed] [Google Scholar]
  9. Minor P. D., Ferguson M., Phillips A., Magrath D. I., Huovilainen A., Hovi T. Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. J Gen Virol. 1987 Jul;68(Pt 7):1857–1865. doi: 10.1099/0022-1317-68-7-1857. [DOI] [PubMed] [Google Scholar]
  10. Roivainen M., Hovi T. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine. J Virol. 1987 Dec;61(12):3749–3753. doi: 10.1128/jvi.61.12.3749-3753.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Roivainen M., Thodén C. J., Stenvik M., Pöyry T., Hovi T. Virus excretion and strain specific antibody responses after oral poliovaccine in previously immunised children. J Med Virol. 1987 Nov;23(3):249–256. doi: 10.1002/jmv.1890230307. [DOI] [PubMed] [Google Scholar]
  12. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Toyoda H., Kohara M., Kataoka Y., Suganuma T., Omata T., Imura N., Nomoto A. Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J Mol Biol. 1984 Apr 25;174(4):561–585. doi: 10.1016/0022-2836(84)90084-6. [DOI] [PubMed] [Google Scholar]
  14. Ukkonen P., Huovilainen A., Hovi T. Detection of poliovirus antigen by enzyme immunoassay. J Clin Microbiol. 1986 Dec;24(6):954–958. doi: 10.1128/jcm.24.6.954-958.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES